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Abstract 
A number of rat hybridomas were adapted to grow in RPMI containing either 5% IgG-depleted FCS or 1% 
serum-free Nutridoma. Alternatively, protein-free Ultradoma PF was used. Growth in these media allowed 
purification procedures to be used that are based on tangential ultrafiltration in combination with affinity 
chromatography on gels linked to protein G or anti-rat L chain coupled antibodies. The isolated antibody 
preparations were found to be pure and to consist of monomeric ntact IgG. The yield and recovery of mAb using 
this procedure were found to be consistently high. These antibody preparations were analyzed for endotoxin 
contamination. Whereas during isolation endotoxin contamination increased, the endotoxin content per mg purified 
protein did not. Affinity chromatography on Detoxi-gel resulted in the efficient removal of this contamination a d 
using this protocol the antibody preparations obtained were found to be of sufficient purity, activity and low 
endotoxin content o permit heir in vivo use in animal models of immunotherapy 
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1. Introduction 
Immunological studies require purified, func- 
tional antibodies. Because of their specificity es- 
pecially monoclonal antibodies (mAbs) can serve 
as crucial reagents for sensitive assays. Moreover, 
studies involving neutralization of biological activ- 
* Corresponding author. Fax: 31-10-436 7601. 
Abbreviations: mAb, monoclonal ntibody; FCS, fetal calf 
serum; SEC, size exclusion chromatography. 
ities in vivo are dependent on large amounts of 
specific and active antibody preparations. There- 
fore, there is a constant need for procedures that 
enable fast, reliable and easy procedures for puri- 
fying mAbs from supernatants of hybridoma cul- 
tures. These purification procedures should result 
in biologically active antibody on a semi-prepara- 
tive scale. In our studies of the in vivo neutraliza- 
tion of cytokines we need mAb in 100 mg quanti- 
ties, that are electrophoretically pure and retain 
their capacity to neutralize cytokine activities in 
vivo. 
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Numerous methods exist for the purification of 
mAb from culture supernatants on an analytical 
and semi-preparative scale (Goding, 1986; Jiskoot 
et al., 1991a,b). These procedures generally re- 
quire multiple purification steps and the choice 
of technique is dependent on the choice of source 
material, type of immunoglobulin, the degree of 
purity required, the application, etc. (Savelkoul 
and Van der Linde-Preesman, 1987; Coppola et 
al., 1989). Routinely, hybridomas are cultured in 
tissue culture flasks resulting in large volumes of 
diluted antibody. Because of the obligatory use of 
fetal calf serum to allow maximal growth of hy- 
bridoma cells, albumin (2-10 mg/ml, Jiskoot et 
al., 1991b) and bovine IgG (50-150/zg/ml, Darby 
et al., 1993) are the major contaminants in hy- 
bridoma culture supernatants. Albumin compro- 
mises purification procedures by binding tightly 
to hybridoma IgG, while bovine IgG will copurify 
together with hybridoma IgG thereby compromis- 
ing the potential use of protein A or protein G 
columns Q~kerstr6m et al., 1985; Darby et al., 
1993). To avoid the latter problem, expensive 
specific affinity columns have to be prepared. 
Since the use of ascitic fluids as a source of mAbs 
is now discouraged it is likely that culture super- 
natants will increasingly be used as an alternative 
source despite the lower concentrations of mAb. 
Methods of increasing mAb concentrations, e.g., 
roller bottles, hollow fiber systems, etc. have been 
used (Altschuler et al., 1986), but they all require 
a large financial investment and are cost effective 
only when used to produce gram amounts of 
mAb. The development of culture Lifecells (Ko- 
lanko and Symbol, 1987) achieves low production 
costs with higher concentrations of mAb. More- 
over, new media especially designed for culturing 
hybridomas have been developed, culminating in 
the development of serum-flee and even protein- 
free formulations (Chang et al., 1980; Cleveland 
et al., 1983; Hoover and Martin, 1990). The use 
of such media circumvents he need for extensive 
purification procedures and can effectively speed 
up the processing time. 
A disadvantage of using multiple purification 
steps is the increased risk of introducing endo- 
toxin contamination (Friberger, 1985). The main 
sources of such contamination are the water used 
to make up the buffers, pipetting procedures and 
columns used to chromatographically purify the 
antibodies (Schindler and Dinarello, 1989). Those 
mAb preparations intended for in vivo neutraliza- 
tion of cytokine activities can not be used when 
containing such a contamination (Majde, 1992). 
With the development of new endotoxin in- 
hibitors new column matrices have become avail- 
able that are able to reduce the endotoxin con- 
tamination considerably (Morrison and Curry, 
1979; Clauss et al., 1990; Warren et al., 1992). 
In this study we describe the development of a 
quick, reliable and cost-effective way of culturing, 
purifying and testing mAb preparations from hy- 
bridoma culture supernatants. The results show 
that this procedure yields pure, biologically active 
mAb, with a low degree of endotoxin contamina- 
tion. These mAb preparations have been shown 
to be effective and useful for in vivo studies. 
2. Materials and methods 
2.1. Cell lines 
The following rat anti-mouse hybridomas were 
used: anti-IL-4 (11Bll rat IgG1 (Ohara and Paul, 
1985)), anti-IFN-7 (XMG 1.2 rat IgG1 (Cherwin- 
ski et al., 1987)) and anti-CD3 (17A2 rat IgG2b 
(Miescher et al., 1989)). 
All cell lines were non-adherent and were cul- 
tured in Falcon tissue culture flasks (Becton 
Dickinson, Plymouth, England) in RPMI 1640 
medium supplemented with L-glutamine (4 mM), 
pyruvate (0.1 M), penicillin (100 IU/ml), strepto- 
mycin (50 /zg/ml), fl-mercaptoethanol (5 × 10 -5 
M). To this complete RPMI medium was added 
either 5% fetal calf serum (FCS, High Clone, 
Gibco BRL, Paisley, Scotland), IgG low FCS 
(containing _< 10 /zg/ml IgG, HyClone, Logan, 
UT, USA) or 1% (v/v) serum-free Nutridoma-SP 
(Boehringer, Mannheim, FRG). Alternatively, 
Ultradoma PF protein-free medium (BioWhit- 
taker, Walkersville, MD, USA) was used as indi- 
cated in the Results section. Nutridoma, with a 
protein concentration less than 40 ~g/ml for 1% 
working solutions (Hoover and Martin, 1990) and 
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Ultradoma, containing no protein have been 
shown to support higher antibody production than 
conventional FCS containing media (BioWhit- 
taker catalog, 1993). 
2.2. Hybridoma bulk cultures 
Approximately 1.5 × 108 cells (viability > 90% 
as determined by Trypan Blue exclusion) were 
cultured in Falcon tissue culture flasks (175 cm 2) 
and transferred by a Curapharm infusion set 
(Medica Hospital Supplies, Den Bosch, Nether- 
lands) to a 3000 ml Fenwal Lifecell tissue culture 
flask (Baxter, Fenwal Division, Round Lake, IL, 
USA), in a final concentration f 5 × 104 cells/ml 
(total volume 1500 ml) as described above. The 
flask was made of polyolefin plastic and designed 
to be highly gas permeable. Absence of my- 
coplasma contamination was verified periodically 
in all cultures using the MycoTect kit (Gibco). 
After culturing for periods of up to 10 days at 
37°C in 5% CO a, culture supernatants were har- 
vested by centrifugation for 10 min at 1500 rpm 
and kept at -20°C until further purification. 
Under these conditions no change of culture 
medium was found to be necessary. 
For comparison Falcon tissue culture flaks (175 
cm a) were used under similar conditions. The 
cells were washed and resuspended in flesh 
medium every 3-4 days. 
2.3. Purification o f  mAb 
Supernatants were concentrated using the 
Minitan Ultrafiltration System (Millipore, Bed- 
ford, MA, USA) using four polysulfone mem- 
branes (PTHK OMT 05, cut-off at 100 kDa) 
operating at a back pressure of 5 psi with a 
retentate rate of 800 ml/min. The supernatants 
(routinely 3000 ml) were concentrated up to ten 
times the initial volume within 2.5 h. 
The mAb from supernatants of hybridoma cul- 
tures that did not grow in Ultradoma were puri- 
fied by affinity chromatography. The mAb were 
purified using a 15 ml bed volume protein G 
column (Immunopure, Pierce, Rockford, IL, 
USA) equilibrated in binding buffer (50 mM 
sodium acetate buffer, pH 5.0). The supernatant 
was applied to the column at a constant flow rate 
of 1.5 ml/min and the OD280 signal was moni- 
tored continuously with a UV-1 monitor equipped 
with a 1 ml flow cell (Pharmacia, Uppsala, Swe- 
den). Bound IgG was eluted using 0.1 M glycine- 
HCI buffer (pH 2.5) and immediately neutralized 
with a few drops of 1 M Tris (pH 11.2). The 
column was regenerated by washing with 5 vols. 
of binding buffer and stored at 4°C in 0.2% 
sodium azide. Alternatively, a 5 ml bed volume 
affinity column of mouse anti-rat (x) L chain 
coupled to cyanogen bromide activated Sepharose 
(Pharmacia) was prepared according to the man- 
ufacturer's instructions. The column was coupled 
with 44 mg of purified mAb RG7 7.6 (Springer et 
al., 1982) and was found to have a binding capac- 
ity of 4 mg rat Ig. The running and elution 
conditions used were identical to the ones used 
for the protein G column. The purified material 
was subsequently dialysed overnight at 4°C against 
PBS. 
The purity of isolated mAbs was confirmed by 
SDS-polyacrylamide g l electrophoresis run un- 
der reducing conditions on 12.5% homogeneous 
gels using Phastsystem (Pharmacia). Gels were 
silver stained according to the manufacturers' 
instructions. Alternatively, the presence of mono- 
meric undamaged IgG was confirmed by size 
exclusion chromatography (SEC) using a Su- 
perdex 200 HR10/30 column and the FPLC sys- 
tem (Pharmacia). The column (V o = 7.8 ml, V t --- 
20.7 ml) was connected to a standard FPLC sys- 
tem consisting of a LCC liquid chromatography 
controller, two P-500 pumps, a MV-7 injector 
equipped with a 200 /zl sample loop, a UV-1 
monitor at 280 nm and 0.1 AUFS (absorption 
units full scale) sensitivity and a FRAC-100 frac- 
tion collector. Isocratic elution at a flow rate of 1 
ml/min at room temperature (23 + 2°C) was per- 
formed with 10 mM phosphate-buffered saline 
containing 150 mM NaCI (PBS), pH 7.3. The 
molecular mass of the eluted peaks (V e) was 
calculated from KAv= (g  e - Vo)/ (W t - V o) and 
the selectivity curve KAv= 2.31-0.38 log M r. 
For long-time storage at -70°C, purified IgG 
was concentrated to at least 1 mg/ml in PBS 
through an Amicon YM10 filter (Amicon, Dan- 
vers, MA, USA). The protein concentration was 
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determined spectrofotometrically using an 
OD28on m extinction coefficient of 1.36 at 1 
mg/ml. 
2.4. Rat IgG1 ELISA 
Microtiter plates were coated with 4/zg/ml  of 
a purified rat IgGl-specific mouse mAb Mr G1P 
(clone MRG 1; Pharmingen, San Diego, CA, 
USA). Appropriate dilutions of the samples in 
PBS were incubated for 3 h at room temperature. 
Subsequently, 0.5 /zg/ml of a biotin-conjugated 
mouse anti-rat IgL (K chain) mAb (clone MRK 1; 
Pharmingen), and 1 izg/ml of a streptavidin- 
labelled horseradish peroxidase (Jackson Im- 
munological Laboratory, Wetsgrove, PA, USA) 
were used. The substrate 2,2'-azino-di-[3-ethylbe- 
nzthiazoline] (ABTS; Sigma, St. Louis, MO, USA) 
in a 1:1 mixture of 0.2 M NaEHPO 4 and 0.1 M 
citric acid (activated with H20 2) was used for 
color development. The reaction was stopped with 
0.2 M citric acid. A purified rat IgG1 (clone R3 
34; Pharmingen) was used as an isotype-speciflc 
standard. This ELISA has a detection limit of 
1.25 ng/ml of rat IgG1. 
2.5. Endotoxin contamination 
The concentration of contaminating endotoxin 
was determined using the Limulus amebocyte 
lysate (LAL) micromethod as described previ- 
ously (Kreeftenberg et al., 1977; Friberger, 1985). 
Briefly, 20/xl of LAL (sensitivity: 0.125 EU/ml  = 
0.0125 ng/ml; Pyrotell Cape Cod, Woodshole, 
MA, USA) was incubated in flat-bottomed mi- 
crotiter plates (Greiner, Alphen a /d  Rijn, Neth- 
erlands) together with 20/xl of sample for 60 min 
at 37°C. The samples were tested at various dilu- 
tions prepared in pyrogen-free water (Lansberg, 
Uden, Netherlands). As a reference a dilution 
curve starting at 2 EU/ml  of E. coil standard 
endotoxin (Sanbio, Uden, Netherlands) was used. 
After incubation, gel formation indicating an en- 
dotoxin concentration of _ 0.125 EU/ml  was 
visualised by adding 10/xl 0.1% (w/v) chlorophe- 
nol red (Merck, Darmstadt, Germany) and plac- 
ing the plate in a vertical position. At a dose of 
0.125 U/ml  or less, no gel formation occurred. 
The endotoxin concentration was calculated by 
multiplying the dilution factor of the last positive 
endpoints by the LAL sensitivity. 
Endotoxin contamination was removed from 
the antibody preparations by affinity chromatog- 
raphy on a 2 ml bed volume Detoxi-gel column 
(Pierce) using PBS as running buffer. To ensure 
maximum binding efficiency the use of neutral 
buffers (PBS, pH 7.3) containing 150 mM NaC1 
was essential. The column had a binding capacity 
of 2 mg endotoxin/ml gel and was eluted with 
PBS containing 1% (w/v) sodium deoxycholate 
(Sigma). After use the column was stored in pyro- 
gen-free water with 0.2% sodium azide. 
3. Results 
3.1. Optimal culture conditions for mAb production 
by hybridoma cells in Lifecells 
Before using Lifecells, the medium require- 
ments of the various hybridomas were deter- 
mined. To this end, tissue culture flasks (75 cm 2 
seeded with 15 ml containing 5 x 104 cells/ml) 
were seeded with 11Bll or 17A2 cells, adapted 
over five splittings to growth in RPMI containing 
5% normal FCS or 5% IgG-depleted FCS or in 
Ultradoma medium free of protein. After several 
days of culture the rat Ig produced in the super- 
natant was assayed with a specific ELISA. 
Yield of IgG in different media 
[] 5% FCS 
[] 5% IgG FCS 
Ultradoma 
m 
o ~ i 2 4 r 
days 
Fig. 1. Cultures of 11Bll cells (at 5×104/ml in 15 ml) 
adapted toUltradoma or RPMI medium containing either 5% 
FCS or 5% IgG-depleted FCS were grown in 75 cm 2 culture 
flasks. Rat IgG1 levels (/.tg/ml) were determined byELISA. 
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The results of the 11Bll cultures howed that 
after 7 days of culture the supernatants of cells ,00 
grown in Ultradoma had accumulated similar 
amounts of mAb to those grown in normal FCS ,~ 
(Fig. 1). Another rat IgG1, XMG 1.2, could 
equally well be adapted to grow in Ultradoma 
(data not shown). The only difference was that _ ~= ~0 
cultures grown in Ultradoma grew more slowly 
than those in normal FCS. The cells cultured in 25 
IgG-depleted FCS consistently produced less 
mAb than those grown in the other media. Sur- 
prisingly, the rat IgG2b secreting 17A2 hy- 
bridoma cells did not survive in the Ultradoma 
medium, athough they were adapted to the 
medium. We have tested three different rat 
IgG2a-and IgG2b-secreting hybridomas and none 
could be adapted to growth in Ultradoma medium 
(data not shown). On the other hand, these rat 
hybridomas could easily be adapted to grow in 
RPMI containing IgG-depleted FCS. 
Lifecells were used according to the manufac- 
turer's instructions: a 3 liter cell was filled with 
1500 ml of medium containing ceils at a seeding 
density of 5 × 10 4 per ml. Lifecells as well as 175 
cm 2 tissue culture flasks containing 25 ml of 
medium were seeded with l lB l l  cells in Ultra- 
doma or RPMI containing 1% (v/v) Nutridoma. 
At various times viability was determined (Table 
Table 1 
Viability of hybridoma cells cultured in Lifecells and flasks 
Days of  Nutridoma Ultradoma 
culture Culture flask Culture flasks Lifecells 
Cells X % Cells x % Cells x % 
104/ml 104/ml 104/ml 
0 5 90 5 95 5 85 
1 8 90 6 95 nd nd 
2 15 80 16 80 6 90 
3 18 70 43 60 nd nd 
4 15 56 19 40 9 90 
6 nd a nd nd nd 29 75 
7 nd nd nd nd 45 60 
10 nd nd nd nd 51 25 
l lB l l  cells were cultured in Nutridoma or Ultradoma 
medium. Viability was assessed using the Trypan blue exclu- 
sion test in a hemocytometer. Cultures were performed either 
in flasks (and followed for 4 days) or in Lifecells (and followed 
for 9 days). 
a Not done. 
Yield of IgG in culture 
D culture flask 
1~ Uf~oII 
o 2 cla4ys 7 ~o 
Fig. 2. Cultures of 11Bll cells adapted to Ultradoma were 
grown in culture flasks (125 cm 2 with 25 ml of 5 x 104 cells/ml) 
or in Lifecells (1500 ml with 5 × 104 cells/ml). Rat IgG1 levels 
(/zg/ml) were determined in ELISA. 
1) and rat IgG1 concentrations in the Ultradoma 
containing cultures were determined using a spe- 
cific ELISA (Fig. 2). The results show that al- 
though the viability of the cultures in Lifecells 
had dropped considerably by day 10, the accumu- 
lated mAb level was high (96 /xg/ml). It was 
found that when the hybridoma cells were 
adapted to grow in Ultradoma PF or RPMI sup- 
plemented with Nutridoma, both media were 
equally effective in sustaining cellular prolifera- 
tion and viability (Table 1). The cultures in the 
conventional culture flasks had to be split after 4 
days of culture after which the data for viability 
and mAb production became irrelevant. By com- 
paring the results in the conventional flasks and 
those of Lifecells it became apparent hat pro- 
duction levels were approximately the same. Nev- 
ertheless, ince Lifecell cultures can stay produc- 
tive for up to 10 days without the need for split- 
ting many culture flasks would be needed to 
equal the production of one Lifecell. Accordingly, 
Lifecells were considered to be superior. 
3.2. Purification of mAb from Lifecell culture su- 
pernatants 
The purification procedure that we employed 
in this study was based on concentrating the 
culture supernatants in a Minitan tangential fil- 
tration system using a 10 5 kDa cut-off mem- 
brane. This membrane nsured rapid concentra- 
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tion with good retention of immunoglobulins and 
little albumin contamination. Subsequently, the 
Ig was further purified by affinity chromatogra- 
phy (when the Ultradoma medium could not be 
used) either on protein G or anti-K L chain 
immobilized Sepharose. Finally, the Ig was con- 
centrated by Amicon ultra filtration. Purity was 
checked by SDS-PAGE analysis, while size exclu- 
sion chromatography permitted analysis of the 
degree of monomeric IgG and confirmed the 
molecular weight (Savelkoul and Breedland, un- 
published observations). 
Depending on the ability of hybridomas to 
adapt o growth in Ultradoma or RPMI contain- 
ing IgG-depleted FCS, the purification procedure 
employed contained no affinity chromatography 
step or was dependent on the use of protein G 
only. The use of this matrix was imperative since 
rat IgG1 antibodies bind in appreciable amounts 
to protein G. In order to bind antibodies to 
protein G columns without loss of binding activ- 
ity, several binding buffers were tested for the 
recovery of functional IgG. To this end, rat IgG1 
antibodies present in 20 ml crude culture super- 
natants diluted 1/2 in various binding buffers 
were allowed to bind to a 1 ml protein G test 
column. All columns were eluted with 0.1 M 
glycine-HCl, pH 2.5 (Table 2). From this study it 
became apparent that using 50 mM acetate 
yielded the highest levels of IgG with good func- 
tional activity in the ELISA procedure. 
Table 2 
Optimal buffer combination for protein G affinity chromatog- 
raphy 
Buffer combination pH Eluate Recovery 
(% OD280) IgG(% in 
eluate) 
50 mM sodium acetate 5.0 63 85 
50 mM acetate+0.1 M 5.0 47 90 
EDTA + 3 M NaCI 
0.01 MPBS(0.15 MNaCI) 7.2 30 78 
0.01 M PBS + 3 M NaCI 7.2 50 80 
50 mM Tris-HC! + 0.1 M 7.8 60 67 
EDTA+0.15 M NaCI 
Recovery is expressed in terms of IgG content as a percentage 
of the IgG1 level in unseparated culture supernatant. IgG1 
levels were determined in an ELISA. 
Table 3 
Yield and recovery during the various purification steps of rat 
IgG2b mAb 
Purification Volume IgG content Yield Recovery 
step (ml) (tt/ml) (/zg) (%) 
Supernatant 3 000.0 20.3 60 900 100.0 
Minitan 380.0 115.3 43814 71.9.0 
Anti-L chain 62.8 649.6 40803 67.0 
column 
Amicon 11.9 3 229.9 38 436 63.1 
Purification and production of IgG from 3 liter culture super- 
natant of 17A2 cells cultured for 10 days in RPMI supple- 
mented with 5% (IgG depleted) FCS in two Lifecells. 
The isolation of rat IgG1 mAb from 11Bll 
cells, adapted to grow in Ultradoma, consisted 
mainly of concentrating the culture supernatants 
in Minitan and Amicon systems. This procedure 
was found to be sufficient o yield pure IgG1. 
When the hybridoma could not be adapted to 
growth in Ultradoma medium, IgG-depleted FCS 
was used as a serum source. In combination with 
Minitan ultrafiltration and protein G affinity 
chromatography (using the above mentioned 
binding buffer system), the rat IgG could be 
Table 4 
Influence of protein purification on cumulated endotoxin 
contamination 
Purification step Volume IgG1 Endo- Contami- 
(ml) content oxin nation 
(mg) (ng/ (ng endo- 
ml) toxin/ 
mg Ig) 
XMG 1.2 (rat IgG1) 
Crude supernatant 
Minitan concentration 
Protein G column 
Amicon filtration 
17A2 (rat IgG2b) 
Crude supernatant 
Minitan concentration 
anti-L chain column 
Amicon filtration 
650 94 0.2 1.38 
160 92 0.8 1.39 
25 18 1.2 1.58 
15 13 1.6 1.85 
3 000 60.9 0.4 19.7 
380 43.8 0.8 6.9 
63 40.8 1.6 2.5 
12 38.4 3.2 1.0 
XMG 1.2 (rat IgG1) and 17A2 (rat IgG2b) hybridoma cells 
were cultured in RPMI + 5% (IgG-depleted) FCS for 10 days 
either in 75 cm 2 culture flasks (15 ml with 5 x 104/ml) or in 
two LifeceUs, respectively. Endotoxin contamination was de- 
termined by LAL assay. 
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purified in high yield with good recovery of bio- 
logical activity. 
Affinity chromatography on immobilized anti-L 
chain antibodies was employed for rat IgG2b 
hybridoma supernatants. Table 3 shows data on 
rat IgG2b antibodies purified from medium con- 
taining 5% IgG-depleted FCS using affinity chro- 
matography on anti-L chain-Sepharose. As is clear 
from these data, the mAb could be purified in 
high yield and recovery of biological activity. 
Analysis on SDS-PAGE and size exclusion chro- 
matography on FPLC equipped with a Superdex 
200 column revealed a preparation of pure (M r = 
160 kDa, Hy  chain = 50 kDa) homogeneous and 
intact IgG molecules. 
3.3. Endotoxin contamination and removal 
It has been previously observed that endotoxin 
contamination of antibody preparations can 
severely compromise studies on the activity of 
cytokines in vivo. To determine endotoxin con- 
tamination levels during routine culturing and 
purification of mAb, cultures of XMG 1.2 and 
17A2 were started in flasks and Lifecells. Subse- 
quently, the Ig was purified using Minitan ultra- 
filtration, affinity chromatography on either pro- 
tein G or anti-L chain columns and Amicon ultra- 
filtration. The results (Table 4) show that during 
the isolation procedure the endotoxin contamina- 
tion steadily increased. Endotoxin contamination 
Table 5 
Removal of endotoxin contamination byDetoxi affinity chro- 
matography 
Sample Endotoxin Detoxi-gel Endotoxin 
(ng/ml) (ng/ml) 
LPS 10.1 Effluent < 0.125 
Eluate 8.6 
17A2 3.2 Effluent < 0.125 
Eluate 2.95 
A Detoxi-gel (2 ml) column was used to remove ndotoxin 
contamination (as determined by LAL assay with a detection 
limit of 0.125 ng/ml) from 1 ml of purified 17A2 protein 
preparation (1mg/ml). A standard LPS preparation contain- 
ing 100 EU/ml (10 ng/ml) was used as a control. PBS was 
used as running buffer. 
was of the order of 1-2 ng per mg of purified Ig. 
Since in vivo antibody treatment in mice is mostly 
performed with doses of 0.2-1 mg per mouse, the 
endotoxin content would vary between 0.2-2 ng 
(2-20 EU) per mouse. 
Preparations of 17A2 mAb containing > 2 ng 
endotoxin per mg of purified Ig were subjected to 
affinity chromatography on a 2 ml bed volume 
Detoxi-gel in PBS. An LPS standard (containing 
100 EU/ml )  was also chromatographed as a con- 
trol (Table 5). The results suggest hat single-step 
affinity chromatography could be used to reduce 
endotoxin contamination in the LPS standard 
from 100 EU/ml  to 1.25 EU/ml .  This corre- 
sponds to a removal efficiency of 85%. The endo- 
toxin contamination in purified mAb prepara- 
tions was reduced to levels (< 1 ng) which would 
be suitable for in vivo applications. 
4. Discussion 
The in Vitro growth and maintenance of cells 
was initially achieved by supplementing culture 
media with poorly defined fluids such as bovine 
serum. The variable composition of serum can 
cause inconsistencies between hybridoma culture 
conditions and create difficulties in the purifica- 
tion and quantification of secreted mAb. Differ- 
ent batches of FCS display a large variation (up 
to four-fold) in their IgG content. Therefore, 
assessment of the bovine IgG content before us- 
ing a batch of FCS might be worthwhile. More- 
over, the use of FCS carries the risk of introduc- 
ing contaminants such as viruses and mycoplasma 
(Samoilovitch et al., 1987). The ability to grow 
hybridomas readily in standard media suggests 
that these cells have simple growth requirements, 
and this has been confirmed by a number of 
studies (Kawamoto et al., 1986; Kovar and Franek, 
1986). Due to differing growth requirements of 
different cell lines these preparations have not 
been satisfactory. With the development of Nu- 
tridoma and Ultradoma new serum-free and even 
protein-free media have been developed that sup- 
port antibody production. Serum-free media con- 
sist of a complete nutrient formulation (consisting 
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of one or more component mixtures) capable of 
supporting cellular proliferation and/or biologi- 
cal production without serum supplementation r 
further addition of growth factors. Such formula- 
tions may contain purified natural or recombi- 
nant growth factors or less well-defined serum 
fractions or tissue or organ extracts. Serum-free 
medium cannot contain serum of any kind from 
any source. Protein-free media consist of a com- 
plete nutrient formulation (consiting of one or 
more component mixtures) capable of supporting 
cellular proliferation and/or  biological produc- 
tion that contains all biochemically defined ingre- 
dients and absolutely no polypeptide components. 
Protein-free media do not contain albumin, in- 
sulin, transferrin, fetuin, peptide growth factors, 
or immunoglobulins. The serum-free Nutridoma 
medium favors three compounds: transferrin, al- 
bumin and insulin. To these compounds odium 
selenite and sometimes hormones are added. 1% 
of this supplement can replace 10% FCS in sup- 
porting cell growth and mAb production. Small 
alterations in the medium, and in other growth 
conditions uch as pH and temperature may stress 
the cells and make them less stable. Since a key 
factor in the consistency of mAb production is 
the stability of the cell line, there is a need for 
rigorous quality control of the culture media. 
Furthermore, preliminary studies have shown that 
the methods described here for rat hybridomas 
are also applicable to mouse hybridomas. When 
using either of the serum-free formulas, cell 
growth appeared to be slower, but antibody pro- 
duction was generally enhanced as observed pre- 
viously by using different formulations (Tharakan 
et al., 1986). It has been suggested (Hoover and 
Martin, 1990) that slower cell growth is beneficial 
for mAb production since it sustains longer cul- 
ture times and permits the use of Lifecells. The 
Lifecell can be used both as a seed vessel and as 
a replacement for large T flasks, spinner flasks 
and small bioreactors (Kolanko and Symbol, 1987; 
Samoilovitch et al., 1987). 
Culture supernatant for mAb purification con- 
tains in addition to the media components, cellu- 
lar DNA and proteins, endotoxin and protein 
species uch as aggregates, fragments and dena- 
tured products (Scott, 1987). The isolation proce- 
dures for mAbs intended for in vivo usage or as 
critical assay reagents usually includes SEC as 
one of the essential steps (either for purification 
or for desalting the final product (Schachter, 1986; 
Coppola et al., 1989)). The disadvantages of this 
approach are the low sample volumes that can be 
processed (1-2% of the column volume), the high 
protein concentration of the sample that is re- 
quired (1-10 mg/ml), and the use of long columns 
to minimize dilution but which result in long run 
times. A high resolution matrix, such as Superdex 
200, in combination with FPLC provides a narrow 
elution profile for the material of interest. More- 
over, run times of up to 1 h can still lead to 
sufficient resolution (Savelkoul and Breedland, 
unpublished observations). Furthermore, the ma- 
trix is useful in the structural analysis of the 
isolated mAb. The removal of endotoxin contami- 
nation is most efficiently achieved by specific 
affinity chromatography on a polymyxin B col- 
umn. SEC will also help remove antibody-related 
contaminants such as antibody aggregates and 
fragments that may have the same surface charge 
characteristics a the intact mAb (Hanna et al., 
1992). 
Endotoxins are pyrogenic lipopolysaccharide 
components of gram-negative bacteria. Since 
these bacteria re ubiquitous in nature, it is not 
surprising that endotoxins are frequent contami- 
nants of biochemical preparations. Maintaining a
low endotoxin concentration is extremely impor- 
tant if in vivo studies are to be performed. Even 
at doses of only ng/ml, they have been shown to 
exert large biological effects in animals and in 
cell cultures. Eliminating contamination of mac- 
romolecular endotoxins from aqueous olutions is 
impossible by ultrafiltration when these solutions 
contain proteins or other macromolecules (Schin- 
dler and Dinarello, 1989). Techniques, such as 
size exclusion chromatography usually introduce 
as much contamination as they remove. Affinity 
chromatography, using an immobilized ligand 
which has a unique specificity for pyrogens is 
effective in the removal of pyrogens from solution 
(Clauss et al., 1990; Warren et al., 1992). Alterna- 
tively, the polycation polymyxin B is frequently 
used to neutralize the contaminating endotoxins. 
The action of polymyxin B depends upon its 
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charge neutral izat ion of the electronegative phos- 
phate groups of the lipid A component  (Morrison 
and Curry, 1979). 
The LAL assay can be effectively used for 
direct detection of contaminat ing endotoxins in 
many products. Recent observations have indi- 
cated that some cytokines, such as tumor necrosis 
factor a,  can synergize with contaminat ing endo- 
toxins at levels not reliably detected by the LAL 
test (Rothstein and Schreiber, 1988). Therefore, 
LAL negativity does not guarantee the absence of 
an endotoxin effect. Immunological  studies can 
be further confounded by other contaminat ing 
microbial cell wall products that do not react in 
the LAL test but do efficiently induce cytokine 
production, e.g., peptidoglycans and mycoplasmal 
products (Dinarel lo and Krueger, 1986). 
Monoclonal  antibodies are relatively complex 
proteins and the stability of both the cell culture 
process and antibody product ion is important.  In 
this study we have shown that the application of 
serum-free and protein-free media in combina- 
tion with cell culturing in Lifecells permits suffi- 
cient cell growth and mAb production. Secondly, 
the use of ultrafi ltration and affinity chromatog- 
raphy resulted in high yields of functionally active 
mAbs. 
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